<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Pulmatrix Inc — News on 6ix</title>
<link>https://6ix.com/company/pulmatrix-inc</link>
<description>Latest news and press releases for Pulmatrix Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/pulmatrix-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835b28b78dffbe2df112367.webp</url>
<title>Pulmatrix Inc</title>
<link>https://6ix.com/company/pulmatrix-inc</link>
</image>
<item>
<title>Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger</title>
<link>https://6ix.com/company/pulmatrix-inc/news/pulmatrix-announces-closing-of-preferred-stock-transaction-as-part-of-planned-merger</link>
<guid isPermaLink="true">https://6ix.com/company/pulmatrix-inc/news/pulmatrix-announces-closing-of-preferred-stock-transaction-as-part-of-planned-merger</guid>
<pubDate>Tue, 21 Apr 2026 12:00:00 GMT</pubDate>
<description>Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), today announced the closing of its previously announced private placement of Series B Convertible Preferred Stock ("Series B Preferred Stock") with an affiliate of Eos SENOLYTIX, Inc. ("Eos"), which such transaction is a part of its planned merger with Eos. The Series B Preferred Stock is convertible into common stock at a price per share of $2.20.</description>
</item>
<item>
<title>PULM Stock Alert: Halper Sadeh LLC is Investigating Whether Pulmatrix, Inc. is Obtaining a Fair Price for its Shareholders</title>
<link>https://6ix.com/company/pulmatrix-inc/news/pulm-stock-alert-halper-sadeh-llc-is-investigating-whether-pulmatrix-inc-is-obtaining-a-fair-price-for-its-shareholders</link>
<guid isPermaLink="true">https://6ix.com/company/pulmatrix-inc/news/pulm-stock-alert-halper-sadeh-llc-is-investigating-whether-pulmatrix-inc-is-obtaining-a-fair-price-for-its-shareholders</guid>
<pubDate>Mon, 13 Apr 2026 13:55:00 GMT</pubDate>
<description>NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Pulmatrix, Inc. (NASDAQ: PULM) and Eos SENOLYTIX, Inc. </description>
</item>
<item>
<title>Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan</title>
<link>https://6ix.com/company/pulmatrix-inc/news/pulmatrix-and-eos-senolytix-announce-merger-agreement-to-advance-novel-mitochondrial-therapies-to-improve-healthspan</link>
<guid isPermaLink="true">https://6ix.com/company/pulmatrix-inc/news/pulmatrix-and-eos-senolytix-announce-merger-agreement-to-advance-novel-mitochondrial-therapies-to-improve-healthspan</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>Combined company to operate as Eos SENOLYTIX, a first-in-class anti-aging biotechnology company$19 million financings to advance lead clinical candidate</description>
</item>
<item>
<title>Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities</title>
<link>https://6ix.com/company/pulmatrix-inc/news/pulmatrix-announces-termination-of-prior-planned-merger-and-continues-pursuit-of-alternative-merger-opportunities</link>
<guid isPermaLink="true">https://6ix.com/company/pulmatrix-inc/news/pulmatrix-announces-termination-of-prior-planned-merger-and-continues-pursuit-of-alternative-merger-opportunities</guid>
<pubDate>Mon, 02 Mar 2026 05:00:00 GMT</pubDate>
<description>Cullgen had been seeking approval for a merger with Pulmatrix from the China Securities Regulatory Commission and on February 28, 2026, notified Pulmatrix</description>
</item>
<item>
<title>Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/pulmatrix-inc/news/pulmatrix-announces-year-end-and-fourth-quarter-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/pulmatrix-inc/news/pulmatrix-announces-year-end-and-fourth-quarter-2025-financial-results</guid>
<pubDate>Thu, 26 Feb 2026 13:05:00 GMT</pubDate>
<description>Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced year-end and fourth quarter financial results for 2025 and provided a corporate update.</description>
</item>
<item>
<title>Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives</title>
<link>https://6ix.com/company/pulmatrix-inc/news/pulmatrix-cullgen-continue-pursue-merger-130500397</link>
<guid isPermaLink="true">https://6ix.com/company/pulmatrix-inc/news/pulmatrix-cullgen-continue-pursue-merger-130500397</guid>
<pubDate>Thu, 18 Dec 2025 13:05:00 GMT</pubDate>
<description>Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced that Pulmatrix and Cullgen Inc. ("Cullgen") have mutually agreed to waive the "No Solicitation" clause in the Merger Agreement signed in November 2024 in order to permit each party</description>
</item>
<item>
<title>Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets</title>
<link>https://6ix.com/company/pulmatrix-inc/news/pulmatrix-announces-third-quarter-2025-120500657</link>
<guid isPermaLink="true">https://6ix.com/company/pulmatrix-inc/news/pulmatrix-announces-third-quarter-2025-120500657</guid>
<pubDate>Thu, 16 Oct 2025 12:05:00 GMT</pubDate>
<description>Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced third quarter financial results for 2025 and provided a corporate update.</description>
</item>
<item>
<title>Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets</title>
<link>https://6ix.com/company/pulmatrix-inc/news/pulmatrix-announces-second-quarter-2025-120500809</link>
<guid isPermaLink="true">https://6ix.com/company/pulmatrix-inc/news/pulmatrix-announces-second-quarter-2025-120500809</guid>
<pubDate>Wed, 06 Aug 2025 12:05:00 GMT</pubDate>
<description>Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced second quarter financial results for 2025 and provided a corporate update.</description>
</item>
<item>
<title>Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets</title>
<link>https://6ix.com/company/pulmatrix-inc/news/pulmatrix-announces-first-quarter-2025-120500265</link>
<guid isPermaLink="true">https://6ix.com/company/pulmatrix-inc/news/pulmatrix-announces-first-quarter-2025-120500265</guid>
<pubDate>Thu, 15 May 2025 12:05:00 GMT</pubDate>
<description>Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced first quarter financial results for 2025 and provided a corporate update.</description>
</item>
<item>
<title>Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets</title>
<link>https://6ix.com/company/pulmatrix-inc/news/pulmatrix-announces-end-fourth-quarter-120500329</link>
<guid isPermaLink="true">https://6ix.com/company/pulmatrix-inc/news/pulmatrix-announces-end-fourth-quarter-120500329</guid>
<pubDate>Fri, 21 Mar 2025 12:05:00 GMT</pubDate>
<description>Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced fourth quarter and year-end financial results for 2024 and provided a corporate update.</description>
</item>
<item>
<title>Cullgen Begins Phase 1 Dosing of its Potential First-in-Class, Oral Pan-TRK Protein Degrader for Acute and Chronic Pain</title>
<link>https://6ix.com/company/pulmatrix-inc/news/cullgen-begins-phase-1-dosing-of-its-potential-first-in-class-oral-pan-trk-protein-degrader-for-acute-and-chronic-pain</link>
<guid isPermaLink="true">https://6ix.com/company/pulmatrix-inc/news/cullgen-begins-phase-1-dosing-of-its-potential-first-in-class-oral-pan-trk-protein-degrader-for-acute-and-chronic-pain</guid>
<pubDate>Wed, 22 Jan 2025 05:00:00 GMT</pubDate>
<description>Pain marks the second therapeutic area for Cullgen’s lead protein degrader CG001419 SAN DIEGO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Cullgen Inc. (“Cullgen”), a</description>
</item>
<item>
<title>Pulmatrix and Cullgen Announce Proposed Merger</title>
<link>https://6ix.com/company/pulmatrix-inc/news/pulmatrix-and-cullgen-announce-proposed-merger</link>
<guid isPermaLink="true">https://6ix.com/company/pulmatrix-inc/news/pulmatrix-and-cullgen-announce-proposed-merger</guid>
<pubDate>Wed, 13 Nov 2024 05:00:00 GMT</pubDate>
<description>Merger to create a Nasdaq-listed company focusing on targeted protein degradation technology with three degrader programs in or about to initiate Phase 1</description>
</item>
<item>
<title>Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/pulmatrix-inc/news/pulmatrix-announces-third-quarter-2024-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/pulmatrix-inc/news/pulmatrix-announces-third-quarter-2024-financial-results-and-provides-corporate-update</guid>
<pubDate>Fri, 08 Nov 2024 05:00:00 GMT</pubDate>
<description>Closed transactions with MannKind Corporation validating the potential value of iSPERSE™ technology Pursuing strategic alternatives to further leverage</description>
</item>
<item>
<title>Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/pulmatrix-inc/news/pulmatrix-announces-second-quarter-2024-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/pulmatrix-inc/news/pulmatrix-announces-second-quarter-2024-financial-results-and-provides-corporate-update</guid>
<pubDate>Tue, 13 Aug 2024 04:00:00 GMT</pubDate>
<description>Completed series of transactions with MannKind Corporation validating iSPERSE™ technology and extending projected cash runway into Q4 2026 $12.4 million in</description>
</item>
<item>
<title>Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation</title>
<link>https://6ix.com/company/pulmatrix-inc/news/pulmatrix-announces-cross-license-agreement-and-transfer-of-laboratory-to-mannkind-corporation</link>
<guid isPermaLink="true">https://6ix.com/company/pulmatrix-inc/news/pulmatrix-announces-cross-license-agreement-and-transfer-of-laboratory-to-mannkind-corporation</guid>
<pubDate>Wed, 29 May 2024 04:00:00 GMT</pubDate>
<description>Cross license involves Pulmatrix iSPERSE™ technology and MannKind's Cricket® inhalation device. Pulmatrix transferring leased building, all leasehold</description>
</item>
<item>
<title>Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)</title>
<link>https://6ix.com/company/pulmatrix-inc/news/pulmatrix-announces-peer-reviewed-publication-of-clinical-results-for-its-orally-inhaled-dhe-for-acute-migraine-pur3100</link>
<guid isPermaLink="true">https://6ix.com/company/pulmatrix-inc/news/pulmatrix-announces-peer-reviewed-publication-of-clinical-results-for-its-orally-inhaled-dhe-for-acute-migraine-pur3100</guid>
<pubDate>Wed, 15 May 2024 04:00:00 GMT</pubDate>
<description>Orally Inhaled PUR3100 is associated with rapid systemic PK within the therapeutic window and a mean time to Cmax matching intravenously (IV) administered</description>
</item>
<item>
<title>Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/pulmatrix-inc/news/pulmatrix-announces-first-quarter-2024-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/pulmatrix-inc/news/pulmatrix-announces-first-quarter-2024-financial-results-and-provides-corporate-update</guid>
<pubDate>Fri, 10 May 2024 04:00:00 GMT</pubDate>
<description>$16.3 million in cash and cash equivalents at the end of Q1 2024 providing projected cash runway into Q1 2026 Third amendment made in Q1 to Cipla partnership</description>
</item>
<item>
<title>Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/pulmatrix-inc/news/pulmatrix-announces-year-end-and-q4-2023-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/pulmatrix-inc/news/pulmatrix-announces-year-end-and-q4-2023-financial-results-and-provides-corporate-update</guid>
<pubDate>Thu, 28 Mar 2024 04:00:00 GMT</pubDate>
<description>2023 year-end $19.2 million cash and cash equivalents provide projected cash runway into Q1 2026 3rd amendment to Cipla partnership resulted in the wind down</description>
</item>
<item>
<title>Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives</title>
<link>https://6ix.com/company/pulmatrix-inc/news/pulmatrix-announces-stopping-the-pur1900-phase-2b-study-patient-enrollment-and-closing-the-study-in-agreement-with-partner-cipla-to-preserve-cash-and-facilitate-pursuit-of-strategic-alternatives</link>
<guid isPermaLink="true">https://6ix.com/company/pulmatrix-inc/news/pulmatrix-announces-stopping-the-pur1900-phase-2b-study-patient-enrollment-and-closing-the-study-in-agreement-with-partner-cipla-to-preserve-cash-and-facilitate-pursuit-of-strategic-alternatives</guid>
<pubDate>Mon, 08 Jan 2024 05:00:00 GMT</pubDate>
<description>Cipla to take sole responsibility for development of PUR1900, refocused on markets with greatest unmet need and faster path to approval, in exchange for 2%</description>
</item>
<item>
<title>Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/pulmatrix-inc/news/pulmatrix-announces-third-quarter-2023-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/pulmatrix-inc/news/pulmatrix-announces-third-quarter-2023-financial-results-and-provides-corporate-update</guid>
<pubDate>Thu, 09 Nov 2023 05:00:00 GMT</pubDate>
<description>Patient enrollment for the Phase 2b study of PUR1900 is ongoing with four additional sites added during Q3, totaling seventeen active sites to date in four</description>
</item>
</channel>
</rss>